Mills, Llewellyn
Dunlop, Adrian
Montebello, Mark
Copeland, Jan
Bruno, Raimondo
Jefferies, Meryem
Mcgregor, Iain
Lintzeris, Nicholas
Article History
Accepted: 13 September 2022
First Online: 8 October 2022
Declarations
:
: All the procedures in the study were approved by the South East Sydney Local Health District Human Research Ethics Committee in accordance with the 1964 declaration of Helsinki.All participants provided written consent prior to taking part in the study.
: Not applicable.
: N Lintzeris reports grants from the Australian National Health and Medical Research Council (NHMRC) during the conduct of the study; grants from Camurus, personal fees from Indivior and personal fees from Mundipharma unrelated to the submitted work; and, being the Clinical Director of the Lambert Initiative in Cannabinoid Therapeutics at University of Sydney from 2015 to 2017, was involved in a number of other studies of medical cannabis unrelated to the submitted work. I McGregor reports grants from NHMRC and grants from Lambert Initiative for Cannabinoid Therapeutics during the conduct of the study for projects unrelated to the submitted work; Dr McGregor is a consultant to Kinoxis Therapeutics and has received speaking fees from Janssen. He reports patents to WO2018107216A1, WO2017004674A1 and WO2011038451A1 issued and licensed, and patents to AU2017904438, AU2017904072 and AU2018901971 pending.GW Pharmaceuticals provided study medication but did not sponsor the trial and were not involved in its design, conduct, analysis, or reporting of results.No other authors report conflicts of interest.